Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens

被引：10

作者：

Nash, RA

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA

[2] Univ Washington, Seattle, WA 98195 USA

来源：

BONE MARROW TRANSPLANTATION | 2003年 / 32卷 / Suppl 1期

关键词：

autoimmune diseases; hematopoietic stem cell transplantation; allogeneic; systemic sclerosis;

D O I：

10.1038/sj.bmt.1703949

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Allogeneic hematopoietic stem cell transplantation (HSCT) tests the hypothesis that the replacement of a 'diseased' autoreactive immunological and stem cell compartment with one that is not autoreactive (but potentially attoreactive) can cure severe autoimmune diseases. The primary risks of allogeneic HSCT are the morbidity and morality associated with delayed immune reconstitution and GVHD. Although the risk of complications and mortality is greater than autologous HSCT, studies of allogeneic HSCT should be conducted in selected cases because there is a greater potential for sustained remissions. This review will discuss the anticipated results from allogeneic HSCT by summarizing outcomes in aplastic anemia and chronic myelogenous leukemia as well as a brief description of Seattle's experience with allogeneic HSCT in the first two patients with systemic sclerosis.

引用

页码：S77 / S80

页数：4

共 20 条

[1]

BALDWIN JL, 1977, ARTHRITIS RHEUM, V20, P1043, DOI 10.1002/art.1780200502

[2] Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years [J].